Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Graham

Showing results (1351-1360 of 1,460) with videos related to

Pageof 146
Sort By:
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
Immunity|November 10, 2022
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A virusesSyed M Moin, Jeffrey C Boyington, Seyhan Boyoglu-Barnum, et al.
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
Nature Immunology|February 12, 2019
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
The Lancet. Infectious Diseases|September 4, 2021
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control studyMichela Antonelli, Rose S Penfold, Jordi Merino, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
Nature Immunology|April 14, 2019
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
Science Advances|August 22, 2020
Development of a potent Zika virus vaccine using self-amplifying messenger RNAKate Luisi, Kaitlyn M Morabito, Katherine E Burgomaster, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Pageof 146

Showing results (1351-1360 of 1,460) with videos related to

Sort By:
Pageof 146
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
Immunity|November 10, 2022
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A virusesSyed M Moin, Jeffrey C Boyington, Seyhan Boyoglu-Barnum, et al.
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
Nature Immunology|February 12, 2019
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
The Lancet. Infectious Diseases|September 4, 2021
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control studyMichela Antonelli, Rose S Penfold, Jordi Merino, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
Nature Immunology|April 14, 2019
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
Science Advances|August 22, 2020
Development of a potent Zika virus vaccine using self-amplifying messenger RNAKate Luisi, Kaitlyn M Morabito, Katherine E Burgomaster, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Pageof 146